P-PSMA-101 CAR-T cells

Phase 1Cell therapy

PPoseida Therapeutics, Inc.

P-PSMA-101 CAR-T cells is one of 44 biologic programs targeting Salivary Gland Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Salivary Gland CancerActive, not recruiting

Salivary Gland CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Salivary Gland Cancer

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

—2

Zoladex

TTerSera Therapeutics LLC

Opdivo

3 4

Yervoy

Bristol-Myers Squibb

Phase 2

3 5

Gleevec

Novartis

Phase 2

1 6

Tykerb

Novartis

Phase 2

1 7

Iressa

AstraZeneca

Phase 2

1 8

Nubeqa

Bayer

Phase 2

1 9

Cabometyx

Bristol-Myers Squibb

Phase 2

1 10

Taxol

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Salivary Gland Cancer1 trial

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Terminated·PPoseida Therapeutics, Inc.·Phase 1·NCT04249947·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for P-PSMA-101 CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — P-PSMA-101 CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for P-PSMA-101 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Poseida Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: PPoseida Therapeutics, Inc.

P-PSMA-101 CAR-T cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Salivary Gland Cancer1 trial

References

Drug Info

Quick Facts

Related News